Table 2 Anticoagulation characteristics
Total (n = 346) | DOAC (n = 74) | Vitamin K antagonist (n = 272) | p | ||||
|---|---|---|---|---|---|---|---|
Anticoagulation indication | |||||||
Not specified | 27 | (7.8) | 10 | (13.5) | 17 | (6.2) | |
Atrial fibrillation | 223 | (64.5) | 48 | (64.9) | 175 | (64.3) | |
Thromboembolic event | 74 | (21.4) | 13 | (17.6) | 61 | (22.4) | |
Mechanical heart-valve | 17 | (4.9) | 1 | (1.4) | 16 | (5.9) | |
Coagulopathy | 5 | (1.4) | 2 | (2.7) | 3 | (1.1) | 0.090 |
Additional platelet aggregation inhibitor therapy | |||||||
None | 285 | (82.4) | 62 | (83.8) | 223 | (82.0) | |
Acetylsalicylic acid | 44 | (12.7) | 9 | (12.2) | 35 | (12.9) | |
Clopidogrel | 13 | (3.8) | 1 | (1.4) | 12 | (4.4) | |
Acetylsalicylic acid + Clopidogrel | 4 | (1.2) | 2 | (2.7) | 2 | (0.7) | 0.328 |
Additional heparin | 7 | (2.0) | 1 | (1.4) | 6 | (2.2) | 0.643 |